BAY 607550
BAY 607550 性质
| 沸点 | 680.7±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.24±0.1 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | DMSO:21.65(最大浓度 mg/mL);45.43(最大浓度 mM) 乙醇:10.0(最大浓度 mg/mL);20.98(最大浓度 mM) |
| 酸度系数(pKa) | 14.54±0.20(Predicted) |
| 形态 | 粉末 |
| 颜色 | 白色至浅棕色 |
BAY 607550 用途与合成方法
Ki: 3.8±0.2 nM (PDE2)
Bay 60-7550 (1 μM) increases cGMP in the neuronal cultures compared with control [F(6,14)=12.97, p<0.05 for Bay 60-7550]. Bay 60-7550 in the presence of NMDA (30 μM) results in further increases in cGMP compared with NMDA alone. The NMDA receptor antagonist MK-801 (10 μM) blocks both Bay 60-7550+NMDA-induced elevation in cGMP in neuronal cultures. Compared with untreated control cells, proliferation of PASMCs from IPAH patients is significantly reduced by BAY 60-7550 (1 μM).
The PDE2 inhibitors Bay 60-7550 (1 mg/kg) reverses restraint stress-induced alterations in behavior, resulting in increased percentages of open-arm entries and open-arm time compared with the vehicle + restraint stress condition. In nonstressed mice, Bay 60-7550 produces a dose-dependent increase in percentages of open-arm entries and open-arm time compared with the vehicle-treated group; significant increases are observed at a dose of 3 mg/kg. In nonstressed mice, Bay 60-7550 increases, in a dose-dependent manner, the number of head-dips and time spent head-dipping, compared with vehicle-treated mice; significant increases are observed at doses of 1 and 3 mg/kg.
BAY 607550 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-11-08 | HY-14992 | 1 mg | 930 | ||
| 2024-11-08 | HY-14992 | BAY 607550 | 439083-90-6 | 5mg | 2046 |
